home / stock / vyne / vyne quote
Last: | $2.62 |
---|---|
Change Percent: | -1.6% |
Open: | $2.54 |
Close: | $2.62 |
High: | $2.7682 |
Low: | $2.53 |
Volume: | 34,681 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.62 | $2.54 | $2.62 | $2.7682 | $2.53 | 34,681 | 05-03-2024 |
$2.5 | $2.53 | $2.5 | $2.53 | $2.4 | 29,242 | 05-02-2024 |
$2.53 | $2.5 | $2.53 | $2.57 | $2.5 | 83,587 | 05-01-2024 |
$2.52 | $2.61 | $2.52 | $2.61 | $2.4 | 39,454 | 04-30-2024 |
$2.63 | $2.54 | $2.63 | $2.63 | $2.5303 | 19,253 | 04-29-2024 |
$2.5 | $2.53 | $2.5 | $2.5752 | $2.42 | 15,899 | 04-26-2024 |
$2.47 | $2.52 | $2.47 | $2.8 | $2.41 | 77,467 | 04-25-2024 |
$2.57 | $2.4 | $2.57 | $2.7305 | $2.295 | 384,452 | 04-24-2024 |
$2.32 | $2.31 | $2.32 | $2.36 | $2.2401 | 30,168 | 04-23-2024 |
$2.35 | $2.24 | $2.35 | $2.43 | $2.24 | 27,675 | 04-22-2024 |
$2.25 | $2.26 | $2.25 | $2.34 | $2.25 | 18,999 | 04-19-2024 |
$2.3 | $2.39 | $2.3 | $2.39 | $2.25 | 11,098 | 04-18-2024 |
$2.4 | $2.3327 | $2.4 | $2.5 | $2.3327 | 31,265 | 04-17-2024 |
$2.42 | $2.5 | $2.42 | $2.5 | $2.38 | 33,106 | 04-16-2024 |
$2.57 | $2.85 | $2.57 | $2.85 | $2.43 | 58,530 | 04-15-2024 |
$2.77 | $2.93 | $2.77 | $2.93 | $2.6879 | 28,561 | 04-12-2024 |
$3 | $2.67 | $3 | $3.0199 | $2.56 | 104,623 | 04-11-2024 |
$2.68 | $2.7 | $2.68 | $2.84 | $2.55 | 60,847 | 04-10-2024 |
$2.76 | $2.755 | $2.76 | $2.8 | $2.69 | 28,419 | 04-09-2024 |
$2.74 | $2.78 | $2.74 | $2.8161 | $2.65 | 71,401 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo BRIDGEWATER, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage ...
BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inf...
2023 was a transformative year for VYNE, marked by the achievement of clinical proof-of-concept for VYN201 in vitiligo and a successful financing with a syndicate of leading institutional investors Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q...